C4 Therapeutics
Clinical-stage biopharmaceutical company pioneering targeted protein degradation (TPD) to develop novel therapies for cancer and other diseases, using its proprietary TORPEDO® platform.
Notes
C4 Therapeutics (NASDAQ: CCCC) is a clinical-stage biopharmaceutical company pioneering a new generation of medicines based on targeted protein degradation (TPD). The company's proprietary TORPEDO® (Target ORiented Protein Degrader Optimizer) platform enables the development of small molecules called degraders that selectively destroy disease-causing proteins.
The company was founded in 2015 based on foundational research from Harvard, MIT, and Dana-Farber Cancer Institute. C4 Therapeutics went public in 2020 and has established partnerships with major pharmaceutical companies including Roche, Biogen, Betta Pharma, and Merck KGaA.
Team
- Andrew J. Hirsch - President & Chief Executive Officer
- LinkedIn: linkedin.com/in/andrewhirsch
- Marc Cohen - Chief Financial Officer
- Adam Siddiqui - Chief Scientific Officer
- Stewart Fisher, Ph.D. - Co-founder, Board Member
Additional Research Findings
- NASDAQ: CCCC (publicly traded)
- Founded in 2015, IPO in October 2020
- TORPEDO® platform for targeted protein degradation
- Lead pipeline candidates: Cemsidomide, CFT8919, CFT1946
- Strategic partnerships with Roche, Biogen, Betta Pharma, Merck KGaA
- Focus on oncology therapeutics
- Headquarters in Watertown, Massachusetts (Greater Boston)
- Founded based on research from Harvard, MIT, and Dana-Farber